

# Mireia Castillo-Martin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1881454/publications.pdf>

Version: 2024-02-01

65  
papers

4,855  
citations

147801

31  
h-index

128289

60  
g-index

68  
all docs

68  
docs citations

68  
times ranked

10719  
citing authors

#	ARTICLE	IF	CITATIONS
1	Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells. <i>Cancer Cell</i> , 2012, 22, 373-388.	16.8	368
2	A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. <i>Nature Medicine</i> , 2014, 20, 1130-1137.	30.7	349
3	Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. <i>Journal of Clinical Investigation</i> , 2008, 118, 3051-64.	8.2	319
4	Cross-Species Regulatory Network Analysis Identifies a Synergistic Interaction between FOXM1 and CENPF that Drives Prostate Cancer Malignancy. <i>Cancer Cell</i> , 2014, 25, 638-651.	16.8	293
5	Inactivation of <i>p53</i> and <i>Pten</i> promotes invasive bladder cancer. <i>Genes and Development</i> , 2009, 23, 675-680.	5.9	268
6	Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. <i>Nature Communications</i> , 2015, 6, 6087.	12.8	240
7	An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. <i>Nature Genetics</i> , 2018, 50, 206-218.	21.4	229
8	Molecular pathways of urothelial development and bladder tumorigenesis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 401-408.	1.6	228
9	EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. <i>Nature Communications</i> , 2018, 9, 3503.	12.8	224
10	PTEN counteracts FBXL2 to promote IP3R3- and Ca <sup>2+</sup> -mediated apoptosis limiting tumour growth. <i>Nature</i> , 2017, 546, 554-558.	27.8	182
11	The metabolic co-regulator PGC1 $\beta$ suppresses prostate cancer metastasis. <i>Nature Cell Biology</i> , 2016, 18, 645-656.	10.3	176
12	Identification of PHLPP1 as a Tumor Suppressor Reveals the Role of Feedback Activation in PTEN-Mutant Prostate Cancer Progression. <i>Cancer Cell</i> , 2011, 20, 173-186.	16.8	158
13	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. <i>Nature</i> , 2017, 547, 109-113.	27.8	142
14	Intragenic antagonistic roles of protein and circRNA in tumorigenesis. <i>Cell Research</i> , 2019, 29, 628-640.	12.0	121
15	Distinct Expression Profiles of p63 Variants during Urothelial Development and Bladder Cancer Progression. <i>American Journal of Pathology</i> , 2011, 178, 1350-1360.	3.8	114
16	A Molecular Signature Predictive of Indolent Prostate Cancer. <i>Science Translational Medicine</i> , 2013, 5, 202ra122.	12.4	114
17	Preclinical Analysis of the $\beta$ -Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1565-1575.	4.1	104
18	Inhibition of the autocrine IL-6/JAK2-STAT3/calprotectin axis as targeted therapy for HR <sup>+</sup> /HER2 <sup>+</sup> breast cancers. <i>Genes and Development</i> , 2015, 29, 1631-1648.	5.9	94

#	ARTICLE	IF	CITATIONS
19	FBXW7 Mutations in Melanoma and a New Therapeutic Paradigm. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju107.	6.3	87
20	RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of <i>Pten</i> -Mutant Metastasis. <i>Cancer Discovery</i> , 2014, 4, 318-333.	9.4	83
21	Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. <i>European Urology</i> , 2016, 70, 771-775.	1.9	69
22	The <i>miR-424(322)/503</i> cluster orchestrates remodeling of the epithelium in the involuting mammary gland. <i>Genes and Development</i> , 2014, 28, 765-782.	5.9	66
23	MYC Drives <i>Pten/Trp53</i> -Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. <i>Cancer Discovery</i> , 2015, 5, 636-651.	9.4	65
24	Loss of Sirt1 Promotes Prostatic Intraepithelial Neoplasia, Reduces Mitophagy, and Delays Park2 Translocation to Mitochondria. <i>American Journal of Pathology</i> , 2015, 185, 266-279.	3.8	51
25	Characterization of Desmoglein Expression in the Normal Prostatic Gland. Desmoglein 2 Is an Independent Prognostic Factor for Aggressive Prostate Cancer. <i>PLoS ONE</i> , 2014, 9, e98786.	2.5	43
26	Concordance of Increased B1 Cell Subset and Lupus Phenotypes in Mice and Humans Is Dependent on BLK Expression Levels. <i>Journal of Immunology</i> , 2015, 194, 5692-5702.	0.8	41
27	The MicroRNA 424/503 Cluster Reduces CDC25A Expression during Cell Cycle Arrest Imposed by Transforming Growth Factor $\beta^2$ in Mammary Epithelial Cells. <i>Molecular and Cellular Biology</i> , 2014, 34, 4216-4231.	2.3	39
28	Salvage surgery for local regrowths in Watch & Wait - Are we harming our patients by deferring the surgery?. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1559-1566.	1.0	38
29	<i>PI3K/AKT</i> pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer. <i>Cancer Medicine</i> , 2015, 4, 1258-1271.	2.8	37
30	Biomarkers for bladder cancer management: present and future. <i>American Journal of Clinical and Experimental Urology</i> , 2014, 2, 1-14.	0.4	36
31	The nuclear transport receptor Importin-11 is a tumor suppressor that maintains PTEN protein. <i>Journal of Cell Biology</i> , 2017, 216, 641-656.	5.2	35
32	Zebrafish modeling of intestinal injury, bacterial exposures, and medications defines epithelial in vivo responses relevant to human inflammatory bowel disease. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	2.4	30
33	Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling. <i>American Journal of Pathology</i> , 2016, 186, 3131-3145.	3.8	28
34	A Common MicroRNA Signature Consisting of miR-133a, miR-139-3p, and miR-142-3p Clusters Bladder Carcinoma in Situ with Normal Umbrella Cells. <i>American Journal of Pathology</i> , 2013, 182, 1171-1179.	3.8	26
35	Salvage Surgery With Organ Preservation for Patients With Local Regrowth After Watch and Wait: Is It Still Possible?. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 1053-1062.	1.3	26
36	Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. <i>Cell Cycle</i> , 2013, 12, 1722-1731.	2.6	25

#	ARTICLE	IF	CITATIONS
37	Suppression of <i>CHK1</i> by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. <i>Cancer Discovery</i> , 2015, 5, 550-563.	9.4	24
38	A Genetic Platform to Model Sarcomagenesis from Primary Adult Mesenchymal Stem Cells. <i>Cancer Discovery</i> , 2015, 5, 396-409.	9.4	22
39	<sup>125</sup> I-Np63 Expression is a Protective Factor of Progression in Clinical High Grade T1 Bladder Cancer. <i>Journal of Urology</i> , 2015, 193, 1144-1150.	0.4	21
40	PPAR $\gamma$ Elicits Ligand-Independent Repression of Trefoil Factor Family to Limit Prostate Cancer Growth. <i>Cancer Research</i> , 2018, 78, 399-409.	0.9	20
41	Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR. <i>Oncogene</i> , 2018, 37, 5858-5872.	5.9	20
42	Limited miR-17-92 overexpression drives hematologic malignancies. <i>Leukemia Research</i> , 2015, 39, 335-341.	0.8	19
43	MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway. <i>Cancer Letters</i> , 2022, 525, 46-54.	7.2	19
44	Characterization and comparison of the properties of sarcoma cell lines in vitro and in vivo. <i>Human Cell</i> , 2009, 22, 85-93.	2.7	16
45	PAX7-FKHR fusion gene inhibits myogenic differentiation via NF- $\kappa$ B upregulation. <i>Clinical and Translational Oncology</i> , 2012, 14, 197-206.	2.4	16
46	Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN. <i>Methods</i> , 2015, 77-78, 25-30.	3.8	16
47	Compound haploinsufficiency of <i>Dok2</i> and <i>Dusp4</i> promotes lung tumorigenesis. <i>Journal of Clinical Investigation</i> , 2018, 129, 215-222.	8.2	16
48	Alternate PAX3 and PAX7 C-terminal isoforms in myogenic differentiation and sarcomagenesis. <i>Clinical and Translational Oncology</i> , 2011, 13, 194-203.	2.4	15
49	Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 1036-1044.e3.	1.2	15
50	A BAC-Based Transgenic Mouse Specifically Expresses an Inducible Cre in the Urothelium. <i>PLoS ONE</i> , 2012, 7, e35243.	2.5	12
51	H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases. <i>Journal of Pediatric Urology</i> , 2016, 12, 91.e1-91.e7.	1.1	10
52	Myocardial Amyloid Quantification with Look-Locker Magnetic Resonance Sequence in Cardiac Amyloidosis. Diagnostic Accuracy in Clinical Practice and Histological Validation. <i>Journal of Cardiac Failure</i> , 2018, 24, 78-86.	1.7	10
53	Immunopathologic Assessment of PTEN Expression. <i>Methods in Molecular Biology</i> , 2016, 1388, 23-37.	0.9	8
54	DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 300-300.	1.6	7

#	ARTICLE	IF	CITATIONS
55	PI3K-regulated Glycine N-methyltransferase is required for the development of prostate cancer. <i>Oncogenesis</i> , 2022, 11, 10.	4.9	6
56	Pancreatic intraductal papillary mucinous neoplasm associated colloid carcinoma. <i>Radiology Case Reports</i> , 2021, 16, 2989-2992.	0.6	3
57	The "Immunoscore" in rectal cancer: could we search quality beyond quantity of life?. <i>Oncotarget</i> , 2022, 13, 18-31.	1.8	3
58	Impact of PSMA PET/CT in prostate cancer patient's clinical management: a pictorial essay of interesting cases with histologic confirmation. <i>Clinical and Translational Imaging</i> , 2020, 8, 207-226.	2.1	2
59	Transformed bone marrow cells generate neoplasms of distinct histogenesis. a murine model of cancer transplantation. <i>Stem Cell Research</i> , 2019, 41, 101637.	0.7	0
60	PSMA expression in thyroid nodule. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 270-272.	0.2	0
61	ΔΔΔΔΔ-Me, a Long Range T-Cell Specific Oncogenic Enhancer in T-ALL. <i>Blood</i> , 2014, 124, 487-487.	1.4	0
62	Function of microRNA activity by ActMiR in bladder cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4531-4531.	1.6	0
63	Prognostic significance of PIK3CA mutation in patients with muscle-invasive urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2016, 34, e16002-e16002.	1.6	0
64	Ct2n0 Distal Rectal Cancer - Do Not Believe In Fairy Tales!. <i>Diseases of the Colon and Rectum</i> , 2021, Publish Ahead of Print, e22.	1.3	0
65	The Role of Biobanks in the Fight against COVID-19 Pandemic: The Portuguese Response. <i>Acta Medica Portuguesa</i> , 2021, 35, .	0.4	0